You are here: Industry Insights > Catalent

News List

Juniper Signs Definitive Agreement to be acquired by Catalent americanpharmaceuticalreview
July 11, 2018
Juniper Pharmaceuticals has entered into a definitive agreement with Catalent to acquire all of the outstanding shares of Juniper at a price of $11.50 per share in cash.
Catalent Appoints Madison, WI Facility GM contractpharma
July 03, 2018
Graham Brearley, Ph.D., has been appointed general manager of Catalent Pharma Solutions Madison, WI facility. He will report to Brian Riley, vice president of operations, Biologics & Specialty Drug Delivery.
Catalent Appoints Clinical Supply Services President contractpharma
June 19, 2018
Paul Hegwood has been appointed president of Catalent’s Clinical Supply Services business. He succeeds Mr. Wetteny Joseph, who was named as Catalent’s chief financial officer in February 2018.
Catalent Completes $5.5M Clinical Storage Expansion contractpharma
May 22, 2018
Catalent Pharma Solutions has completed the second phase of a $5.5 million expansion program at its Kansas City, MO facility, increasing controlled-substance and controlled-temperature storage capabilities for its clinical supply business
Catalent announces organizational restructuring cphi-online
May 10, 2018
Catalent Pharma Solutions has announced key organizational changes within its biologics business to further align its organization with customer demand for integrated and comprehensive,
Catalent Bolsters Drug Development Capabilities contractpharma
April 25, 2018
Catalent Pharma Solutions has unveiled plans to invest $5 million in the creation of a new drug development center of excellence (CoE) at its Somerset, NJ facility and headquarters.
M&As this week: Catalent, Ultragenyx Pharmaceutical pharmaceufical-technology
September 25, 2017
The acquisition will strengthen Catalent’s position in the biologics development and analytical services sectors.
Catalent signs agreement to buy Cook Pharmica for $950m pharmaceufical-technology
September 21, 2017
US-based company Cook Group has reached an agreement to divest its drug manufacturing division Cook Pharmica to Catalent for $950m.
Catalent to Acquire Cook Pharmica for $950M contractpharma
September 20, 2017
Expands biologics development and analytical services, manufacturing, and finished product supply
Catalent and academia on quest to better understand pediatric drug formulation and delivery challeng cphi-online
July 21, 2017
Goal of the collaboration is to identify therapies and diseases for which there is a high need for pediatric-friendly formulations.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page